Immix Biopharma's NXC-201 Achieves 95% Complete Response Rate in Pivotal AL Amyloidosis Trial
IMMX has more than doubled off its 52-week low of $1.87.
Summary
Immix Biopharma announced a 95% complete response rate (CR) for its NXC-201 therapy in the NEXICART-2 clinical trial for relapsed/refractory AL Amyloidosis, with 19 out of 20 patients achieving CR. This highly positive interim update follows the completion of enrollment for the NEXICART-2 trial announced in March and a concurrent 8-K filing. NXC-201 already holds FDA Breakthrough Therapy Designation, and this strong data significantly de-risks the drug's path to market. The company plans to initiate a Phase 3 trial and pursue a Biologics License Application (BLA). The next NEXICART-2 update is expected in late September 2026, with BLA submission anticipated by the end of March 2027.
At the time of this announcement, IMMX was trading at $9.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $486.4M. The 52-week trading range was $1.87 to $11.61. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.